Brinker International (NYSE:EAT) reported quarterly earnings of $1.15 per share which missed the analyst consensus estimate of $1.16 by 0.86 percent. This is a 31.55 percent decrease over earnings of $1.68 per share fromBrinker International (NYSE:EAT) reported quarterly earnings of $1.15 per share which missed the analyst consensus estimate of $1.16 by 0.86 percent. This is a 31.55 percent decrease over earnings of $1.68 per share from the same period last year. The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $1.02 billion by 0.15 percent. This is a 1.24 percent increase over sales of $1.01 billion the same period last year.
Pasithea Therapeutics Announces PAS-004 Abstract Accepted For Poster Presentation At 2024 ASCO Annual Meeting
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type
